Ensure that the affected area is clean and dry
Apply a very thin layer of Kelo-cote® to the scar and allow to dry
Twice daily application provides 24 hour coverage via cross-linking polymers

Patients/hospitals may obtain Kelo-Cote® via the following:
- Pressure garments, cosmetics and sunscreen can be applied once Kelo-cote® has dried
- Suitable for use on children and patients with sensitive skin
- Ideal for irregular skin/scar surfaces, joints, flexures and widespread scars

Kelo-cote® - begin the healing now

The Perfect Complement to a Perfect Procedure

<table>
<thead>
<tr>
<th>Product Size</th>
<th>Coverage</th>
<th>Possible Procedure</th>
</tr>
</thead>
<tbody>
<tr>
<td>4g gel</td>
<td>5 - 7.5 linear cm</td>
<td>Hands, Mohs Surgery, Claff Lip Repair, Rhinoplasty</td>
</tr>
<tr>
<td>15g gel</td>
<td>10 - 17.5 linear cm</td>
<td>Breast Augmentation, Face Lift, Brow Lift</td>
</tr>
<tr>
<td>40g gel</td>
<td>59 - 69 linear cm</td>
<td>Hydatidomy, Orthopedic Surgery, Abdominoplasty</td>
</tr>
<tr>
<td>30mL spray* **</td>
<td>7.5 x 12.5 cm area</td>
<td>C-Section, Breast Reduction, Bums</td>
</tr>
<tr>
<td>100mL spray* **</td>
<td>12 x 15 cm area</td>
<td>Post Bariatric, Brachioplastic, Burns</td>
</tr>
</tbody>
</table>

* Spray is a touch-free option ideal for widespread, irregularly shaped and hard to reach scars, as well as scars sensitive to touch.
** Spray is not meant to be used on the face.

Patients/hospitals may obtain Kelo-Cote® via the following:
- Your preferred supplier
  - If your supplier does not carry Kelo-Cote®, please call mediGroup Australia on 1300 362 534

mediGroup Australia
1300 362 534
customer@medigroup.com.au

References
4. Kelo-Cote®. FDA Letter of approval
11. Suqahmarooh M. Komp Dermatologica 2006; 1:30-32

[100% Silicone for Effective Scar Reduction and Abnormal Scar Prevention]

Kelo-cote® advanced formula scar gel

100% Silicone for Effective Scar Reduction and Abnormal Scar Prevention

Also available with SPF 30 sunscreen

Global Clinical Standard for Scar Therapy

Proudly distributed in Australia and New Zealand by:

In Australia, Kelo-Cote® is TGA Registered (ARTG #155514)
Kelo-cote® is effective in speeding up maturation and in reducing the hypertrophy rate of fresh surgical scars. 

Mechanism of action theory

<table>
<thead>
<tr>
<th>Hydration</th>
<th>Protection</th>
<th>Modulation of growth factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normalises collagen production</td>
<td>Forms a barrier against bacterial invasion</td>
<td>Fibroblast production decreases, collagenase production increases, therefore overall collagen production is normalised.</td>
</tr>
</tbody>
</table>

Facial trauma, 2 year old female

1 day post-trauma

Facial trauma, 8 year old

12 weeks post Kelo-cote® treatment

Kelo-cote®

Advanced formula silicone scar gel

- 100% silicone in a unique, patented self-drying formulations
- Found by the FDA to be "substantially equivalent" to silicone sheets
- Clinically proven to work in over 80% of cases
- 100% of physicians rate the tolerability of Kelo-cote® as good or very good
- Effective for both old and new scars, and in the prevention of excessive and abnormal scar formation
- Rattens, softens and smoothes scars as well as reducing associated itching, discomfort and redness
- Binds to skin forming a semi-occlusive, gas permeable waterproof layer, eliminating maceration side effects
- Indicated for scars resulting from surgical and cosmetic procedures, wounds, burns and trauma

Proven efficacy in post-surgical and hard to treat scars

Kelo-cote® significantly reduces all the key scar measurements using the Vancouver scar scale (VSS).

Facial trauma, 2 year old female

Trauma to the palm

Facial trauma, 8 year old

12 weeks post Kelo-cote® treatment

Efficacy confirmed in largest scar study ever conducted, which included 1522 patients

- The physicians evaluated the overall effectiveness as “very good” or “good” in 82.6% of cases, the patients gave an evaluation of “very good” or “good” in 81.4% of the cases. Efficacy was evaluated by measuring typical scar symptoms: difference in colour from the surrounding skin, pliability and height, itchiness and pain/tenderness.
- Physicians evaluated tolerability as “very good” or “good” in 98.7% of the cases, patients reported “very good” or “good” tolerability of scar treatment with Kelo-cote® in 98.2% of the cases, representing high consistency in the evaluations.

Evaluation of contentment after treatment with Kelo-cote®

<table>
<thead>
<tr>
<th>Patient assessment</th>
<th>Physician assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Good</td>
<td>Good</td>
</tr>
<tr>
<td>Very good</td>
<td>Very good</td>
</tr>
</tbody>
</table>

Median change in score of parameters in VSS

Age of scar

- > 24 months
- 12–24 months
- 6–12 months
- < 3 months

Percentage of Patients with Some Degree of Hypertrophy

- Kelo-cote®
- No Treatment

Silicone - The gold standard in scar management

2002 International Clinical Recommendations on Scar Management

- Silicone is the only non-invasive option for which evidence-based recommendations have been made for both scar treatment and prevention.
- Silicone is recommended as first line therapy in the treatment of linear hypertrophic scars, keloids and widespread burn hypertrophic scars
- Silicone gel should be the first line treatment in the initial management of all scars and particularly in the prevention of keloids and hypertrophic scars.